$AFIB
Acutus Medical, Inc.

2019 Q4 Form 10-K Financial Statement

#000156459021014208 Filed on March 19, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q1 2019
Revenue $790.0K $2.836M
YoY Change 30.69%
Cost Of Revenue $2.180M $9.240M
YoY Change 23.04%
Gross Profit -$1.390M -$6.410M
YoY Change 20.04%
Gross Profit Margin -175.95% -226.02%
Selling, General & Admin $4.090M $26.85M
YoY Change 101.4%
% of Gross Profit
Research & Development $4.380M $15.00M
YoY Change -21.38%
% of Gross Profit
Depreciation & Amortization $1.960M $570.0K $2.280M
YoY Change 7.55%
% of Gross Profit
Operating Expenses $8.470M $41.85M
YoY Change 29.12%
Operating Profit -$9.860M -$72.57M
YoY Change 92.24%
Interest Expense -$5.680M $22.27M
YoY Change -551.68%
% of Operating Profit
Other Income/Expense, Net $840.0K -$24.47M
YoY Change 368.77%
Pretax Income -$14.70M -$97.04M
YoY Change 102.54%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.70M -$97.04M
YoY Change 102.54%
Net Earnings / Revenue -1860.76% -3421.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$596.6K -$3.938M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q1 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.80M
YoY Change 305.65%
Cash & Equivalents $9.452M $9.500M
Short-Term Investments $62.40M
Other Short-Term Assets $2.000M
YoY Change 81.82%
Inventory $8.424M $8.400M
Prepaid Expenses
Receivables $263.0K $300.0K
Other Receivables $0.00
Total Short-Term Assets $82.46M $82.50M
YoY Change 276.71%
LONG-TERM ASSETS
Property, Plant & Equipment $4.427M $6.800M
YoY Change 74.36%
Goodwill $12.03M
YoY Change
Intangibles $4.110M
YoY Change
Long-Term Investments
YoY Change
Other Assets $95.00K $100.0K
YoY Change 0.0%
Total Long-Term Assets $23.00M $23.00M
YoY Change 475.0%
TOTAL ASSETS
Total Short-Term Assets $82.46M $82.50M
Total Long-Term Assets $23.00M $23.00M
Total Assets $105.5M $105.5M
YoY Change 307.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.882M $3.900M
YoY Change 143.75%
Accrued Expenses $10.08M $10.60M
YoY Change 120.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due $8.200M
YoY Change
Total Short-Term Liabilities $31.91M $31.90M
YoY Change 28.11%
LONG-TERM LIABILITIES
Long-Term Debt $38.24M $43.90M
YoY Change 200.68%
Other Long-Term Liabilities $2.100M
YoY Change
Total Long-Term Liabilities $38.24M $46.00M
YoY Change 215.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.91M $31.90M
Total Long-Term Liabilities $38.24M $46.00M
Total Liabilities $77.91M $77.90M
YoY Change 97.22%
SHAREHOLDERS EQUITY
Retained Earnings -$259.0M $0.00
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.50M
YoY Change
Total Liabilities & Shareholders Equity $105.5M $105.5M
YoY Change 307.34%

Cashflow Statement

Concept 2019 Q4 2019 Q1 2019
OPERATING ACTIVITIES
Net Income -$14.70M -$97.04M
YoY Change 102.54%
Depreciation, Depletion And Amortization $1.960M $570.0K $2.280M
YoY Change 7.55%
Cash From Operating Activities -$46.41M -$9.580M -$55.99M
YoY Change 65.74%
INVESTING ACTIVITIES
Capital Expenditures -$3.380M -$20.00K $3.395M
YoY Change -266.42%
Acquisitions $3.000M
YoY Change
Other Investing Activities -$75.14M $8.100M -$67.04M
YoY Change 2382.96%
Cash From Investing Activities -$78.51M $8.080M -$70.43M
YoY Change 1385.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 126.3M 0.000 126.3M
YoY Change 237.71%
NET CHANGE
Cash From Operating Activities -46.41M -9.580M -55.99M
Cash From Investing Activities -78.51M 8.080M -70.43M
Cash From Financing Activities 126.3M 0.000 126.3M
Net Change In Cash 1.420M -1.500M -173.0K
YoY Change -84.41%
FREE CASH FLOW
Cash From Operating Activities -$46.41M -$9.580M -$55.99M
Capital Expenditures -$3.380M -$20.00K $3.395M
Free Cash Flow -$43.03M -$9.560M -$59.38M
YoY Change 87.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity File Number
EntityFileNumber
001-39430
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
2210 Faraday Ave.
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2020 dei City Area Code
CityAreaCode
442
CY2020 dei Local Phone Number
LocalPhoneNumber
232-6080
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Entity Registrant Name
EntityRegistrantName
ACUTUS MEDICAL, INC.
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001522860
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q2 dei Entity Public Float
EntityPublicFloat
0
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28095004
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
280000
CY2019 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
0
CY2020 us-gaap Sales Type Lease Income Comprehensive Income Extensible List
SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
CY2019Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
0
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-30000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
126583000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-225811000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
192535000
CY2020 dei Trading Symbol
TradingSymbol
AFIB
CY2019Q4 afib Shortterm Contingent Consideration
ShorttermContingentConsideration
8200000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
933000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
833000
CY2019Q4 afib Common And Preferred Stock Warrant Liability
CommonAndPreferredStockWarrantLiability
8919000
CY2020 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25234000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9452000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
105839000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
62351000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
150000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
150000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2160000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
263000
CY2020Q4 us-gaap Inventory Net
InventoryNet
12958000
CY2019Q4 us-gaap Inventory Net
InventoryNet
8424000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5047000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1816000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
151388000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
82456000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
8726000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12356000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4427000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1669000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2341000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5653000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4110000
CY2020Q4 us-gaap Goodwill
Goodwill
12026000
CY2019Q4 us-gaap Goodwill
Goodwill
12026000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
717000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
95000
CY2020Q4 us-gaap Assets
Assets
192535000
CY2019Q4 us-gaap Assets
Assets
105455000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8266000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3882000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7308000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10076000
CY2020Q4 afib Shortterm Contingent Consideration
ShorttermContingentConsideration
5400000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21907000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31910000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1134000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2054000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39011000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
38244000
CY2020Q4 afib Longterm Contingent Consideration
LongtermContingentConsideration
3900000
CY2019Q4 afib Longterm Contingent Consideration
LongtermContingentConsideration
5700000
CY2020Q4 us-gaap Liabilities
Liabilities
65952000
CY2019Q4 us-gaap Liabilities
Liabilities
77908000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105455000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
363000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33252000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-361015000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259034000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
487290000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27991425
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
695902
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27991425
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
695902
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2836000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33454000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50357000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26847000
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
786000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
97000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
500000
CY2020 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
99797000
CY2019 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
75405000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-91333000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-72569000
CY2020 afib Change In Fair Value Of Warrant Liability And Embedded Derivative
ChangeInFairValueOfWarrantLiabilityAndEmbeddedDerivative
5555000
CY2019 afib Change In Fair Value Of Warrant Liability And Embedded Derivative
ChangeInFairValueOfWarrantLiabilityAndEmbeddedDerivative
1919000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1447000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
436000
CY2019 us-gaap Interest And Other Income
InterestAndOtherIncome
1164000
CY2020 us-gaap Interest Expense
InterestExpense
5506000
CY2019 us-gaap Interest Expense
InterestExpense
22268000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10625000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24470000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101958000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-97039000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-101981000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-97039000
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-53000
CY2019 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
46000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-96000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101671000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97089000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.94
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-144.41
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11407542
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
671953
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-131824000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2994000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2020 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
260555000
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
166286000
CY2020 afib Reclassification Of Warrant Liability To Stockholders Equity
ReclassificationOfWarrantLiabilityToStockholdersEquity
14474000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
634000
CY2019 afib Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-745000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85169000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
12103000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55986000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
114694000
CY2020 afib Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
13000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68735000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
17095000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
45000000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
14700000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11225000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3395000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2111000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2232000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2901000
CY2020 afib Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-820000
CY2020 us-gaap Profit Loss
ProfitLoss
-101981000
CY2019 us-gaap Profit Loss
ProfitLoss
-97039000
CY2020 us-gaap Depreciation
Depreciation
2763000
CY2019 us-gaap Depreciation
Depreciation
2280000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
457000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
250000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
12103000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2994000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-484000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
153000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
767000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
17579000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
684000
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
637000
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000000
CY2020 afib Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
97000
CY2019 afib Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
500000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1897000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
96000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3891000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5421000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3383000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
928000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
622000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2283000
CY2019 afib Payments To Acquire Research And Development License
PaymentsToAcquireResearchAndDevelopmentLicense
10000000
CY2019 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
3000000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63824000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70430000
CY2019 afib Proceeds From Issuance Of Debt And Warrants
ProceedsFromIssuanceOfDebtAndWarrants
77000000
CY2019 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-15000000
CY2019 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2332000
CY2020 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2500000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
66563000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
166286000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
634000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
108000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
164433000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
126339000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
342000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-96000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15782000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-173000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9602000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9775000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25384000
CY2020 us-gaap Interest Paid
InterestPaid
4676000
CY2019 us-gaap Interest Paid
InterestPaid
3593000
CY2019 afib Issuance Of Series D Convertible Preferred Stock For2018 Convertible Notes And2019 Convertible Notes
IssuanceOfSeriesDConvertiblePreferredStockFor2018ConvertibleNotesAnd2019ConvertibleNotes
68476000
CY2020 afib Issuance Of Series D Convertible Preferred Stock For Biotroniks Asset Purchase
IssuanceOfSeriesDConvertiblePreferredStockForBiotroniksAssetPurchase
5000000
CY2020 afib Issuance Of Series D Convertible Preferred Stock For Rhythm Xience Acquisition
IssuanceOfSeriesDConvertiblePreferredStockForRhythmXienceAcquisition
2197000
CY2020 us-gaap Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments
UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
53000
CY2019 us-gaap Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments
UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
-46000
CY2019 afib Rightofuseassets Exchanged For Operating Lease Liabilities
RightofuseassetsExchangedForOperatingLeaseLiabilities
2978000
CY2019 afib Accrued Purchase Of Research And Development License
AccruedPurchaseOfResearchAndDevelopmentLicense
5000000
CY2020 afib Accrued Licensed Intangibles Assets
AccruedLicensedIntangiblesAssets
2000000
CY2020 afib Unpaid Purchases Of Property Plant And Equipment
UnpaidPurchasesOfPropertyPlantAndEquipment
101000
CY2019 afib Unpaid Purchases Of Property Plant And Equipment
UnpaidPurchasesOfPropertyPlantAndEquipment
174000
CY2020 afib Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
643000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
260555000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.72
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
28000000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates and Assumptions </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and disclosures of contingent assets and liabilities. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include, but are not limited to, revenue recognition, useful lives of intangible assets, assessment of impairment of goodwill, provisions for income taxes, measurement of operating lease liabilities, and the fair value of common stock, stock options, warrants, embedded derivative in convertible notes, intangible assets, contingent consideration and goodwill. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, restricted cash, accounts receivable and marketable securities. Cash and restricted cash are maintained in accounts with financial institutions, which, at times may exceed the Federal depository insurance coverage of $0.25 million. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company&#8217;s marketable securities portfolio consists primarily of investments in money market funds, commercial paper, U.S. treasury securities, asset-backed securities and short-term high credit quality corporate debt securities. </p>
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
864000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
311000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
234000
CY2020 us-gaap Lease Cost
LeaseCost
1175000
CY2019 us-gaap Lease Cost
LeaseCost
1098000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1044000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1074000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.60
CY2020 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.80
CY2019Q4 afib Intangible Assets Accumulated Amortization
IntangibleAssetsAccumulatedAmortization
250000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2836000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
640000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
100000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
700000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3047000
CY2020 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-03-25
CY2020Q4 afib Working Capital Deficit
WorkingCapitalDeficit
129500000
CY2019Q4 afib Working Capital Deficit
WorkingCapitalDeficit
50500000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8464000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
640000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
62306000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
640000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
630000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
620000
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2483000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6250000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
45000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
62351000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3785000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
120000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
188000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
301000
CY2020Q4 afib Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
439000
CY2019Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P1Y
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7960000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3731000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5492000
CY2019Q4 afib Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
605000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
196000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
311000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
153000
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
133635000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
9300000
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
169000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1267000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1605000
CY2019Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
151000
CY2019Q4 afib Accrued Purchase Price Liabilities Current
AccruedPurchasePriceLiabilitiesCurrent
5000000
CY2019Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
0
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
468000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
641000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
44550000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
44550000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
71252000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1327000
CY2020 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
800000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
82810000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
114573000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
5539000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
6306000
CY2019Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
59815000
CY2019Q2 afib Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
2379000
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
22819000
CY2019Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
62194000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3000000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3600000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114565000
CY2019Q2 afib Temporary Equity Stock Issued During Period Shares For Convertible Notes
TemporaryEquityStockIssuedDuringPeriodSharesForConvertibleNotes
4108478
CY2020Q4 afib Office Space Subject To Operating Lease
OfficeSpaceSubjectToOperatingLease
50800
CY2020 afib Income Tax Reconciliation Tax Warrants
IncomeTaxReconciliationTaxWarrants
1167000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1013000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
972000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54006000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2978000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
839000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12103000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19589000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10592000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7233000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
367000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6165000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4110000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5653000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
6300000
CY2020Q4 afib Intangible Assets Accumulated Amortization
IntangibleAssetsAccumulatedAmortization
647000
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
4360000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
864000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
338000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
107000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
27000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79782000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
52949000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3028000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2994000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4773681
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1057000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1979000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19177629
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
450000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-102048000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-97091000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
90000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
52000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
642000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-101958000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-97039000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
23000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
53000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-21411000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20378000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2237000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1315000
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1761000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
51000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
51000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2220000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
153000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2067000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
824608
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
956552
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
543793
CY2019 afib Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
419992
CY2019 afib Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
7233
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
122000
CY2020 afib Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
131944
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.10
CY2019 afib Class Of Warrant Or Right Exercise Price Of Warrants Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsGranted
16.67
CY2019 afib Class Of Warrant Or Right Exercise Price Of Warrants Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsExercised
8.29
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.88
CY2020 afib Class Of Warrant Or Right Exercise Price Of Warrants Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsExercised
0.25
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
968000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
567000
CY2019 afib Income Tax Reconciliation Interest Expense
IncomeTaxReconciliationInterestExpense
230000
CY2019 afib Income Tax Reconciliation Tax Warrants
IncomeTaxReconciliationTaxWarrants
253000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
349000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.10
CY2018 afib Weighted Average Remaining Contractual Life Of Warrants
WeightedAverageRemainingContractualLifeOfWarrants
P9Y3M18D
CY2019 afib Weighted Average Remaining Contractual Life Of Warrants Granted
WeightedAverageRemainingContractualLifeOfWarrantsGranted
P8Y6M
CY2019 afib Weighted Average Remaining Contractual Life Of Warrants Exercised
WeightedAverageRemainingContractualLifeOfWarrantsExercised
P5Y1M6D
CY2019 afib Weighted Average Remaining Contractual Life Of Warrants
WeightedAverageRemainingContractualLifeOfWarrants
P8Y4M24D
CY2020 afib Weighted Average Remaining Contractual Life Of Warrants Exercised
WeightedAverageRemainingContractualLifeOfWarrantsExercised
P7Y4M24D
CY2020 afib Weighted Average Remaining Contractual Life Of Warrants
WeightedAverageRemainingContractualLifeOfWarrants
P7Y6M
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7233
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000000
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one voting right
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0035
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.009
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.021
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80
CY2020 afib Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice
28.81
CY2019 afib Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice
14.81
CY2018 afib Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice
11.91
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.58
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
485000
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
16000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
26619000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20500000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5870000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0058
CY2020 afib Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0.0000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-737000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
223000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-237000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-43000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0219
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0135
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0095
CY2020 afib Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
-0.0114
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0072
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0023
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0023
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0019
CY2019 afib Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
-0.0024
CY2020Q4 afib Deferred Tax Liabilities Irc263 A
DeferredTaxLiabilitiesIRC263A
58000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.0173
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.0002
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3028000
CY2019 afib Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
-0.0026
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0576
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0005
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2611
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2111
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0003
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
68727000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45455000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1225000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
720000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7225000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1057000
CY2020 afib Operating Loss Carryforwards Term To Offset Previous Years Income Under Cares Act
OperatingLossCarryforwardsTermToOffsetPreviousYearsIncomeUnderCARESAct
P5Y
CY2020 afib Operating Loss Carryforwards To Offset Taxable Income Percentage Under Cares Act
OperatingLossCarryforwardsToOffsetTaxableIncomePercentageUnderCARESAct
1.00
CY2020 afib Operating Loss Carryforwards To Offset Taxable Income Percentage For Next One Year And Thereafter Under Cares Act
OperatingLossCarryforwardsToOffsetTaxableIncomePercentageForNextOneYearAndThereafterUnderCARESAct
0.80
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1539000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1210000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3116000
CY2020Q4 afib Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Vacation
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedVacation
390000
CY2019Q4 afib Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Vacation
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedVacation
187000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
745000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
484000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
648000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3397000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1523000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
493000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
509000
CY2019Q4 afib Deferred Tax Assets Irc263 A
DeferredTaxAssetsIRC263A
239000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3863000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
3100000
CY2020 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
Since the Company formed in 2011, all filed tax returns are subject to examination. Generally, the tax years remain open for examination by the federal statute under a three-year statute of limitation; however, states generally keep their statutes open for four years. However, the Company’s tax years from inception are subject to examination by the United States and California taxing authorities due to the carry forward of unused NOLs and R&D credits.
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001564590-21-014208-index-headers.html Edgar Link pending
0001564590-21-014208-index.html Edgar Link pending
0001564590-21-014208.txt Edgar Link pending
0001564590-21-014208-xbrl.zip Edgar Link pending
afib-10k_20201231.htm Edgar Link pending
afib-20201231.xml Edgar Link completed
afib-20201231.xsd Edgar Link pending
afib-20201231_cal.xml Edgar Link unprocessable
afib-20201231_def.xml Edgar Link unprocessable
afib-20201231_lab.xml Edgar Link unprocessable
afib-20201231_pre.xml Edgar Link unprocessable
afib-ex1022_510.htm Edgar Link pending
afib-ex1024_509.htm Edgar Link pending
afib-ex1025_508.htm Edgar Link pending
afib-ex211_507.htm Edgar Link pending
afib-ex231_652.htm Edgar Link pending
afib-ex311_506.htm Edgar Link pending
afib-ex312_505.htm Edgar Link pending
afib-ex321_504.htm Edgar Link pending
afib-ex322_503.htm Edgar Link pending
afib-ex43_742.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grafte10fswa000001.jpg Edgar Link pending
grafte10fswa000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending